Novavax investigational COVID-19 vaccine (NVX-CoV2373)

NVX-CoV2373 is a protein-based vaccine targeting SARS-CoV-2, the virus that causes COVID-19. Recombinant technology is used to create vaccine protein antigens, which are arranged around a nanoparticle core and then formulated with Matrix-M™ adjuvant to create the ready-to-use NVX-CoV2373 vaccine. Recombinant technology is used to create vaccine nanoparticles, which are then mixed with Matrix-M™ adjuvant to create the ready-to-use NVX-CoV2373 vaccine. NVX-CoV2373 is still under investigation in the United States and is not authorized for use. For Global authorizations, please refer to the global vaccine authorization/approval map.

• 1

  SARS-CoV-2 spike protein gene inserted into insect virus

  The full-length, stabilized spike gene is engineered into baculovirus.

  
• 2

  Sf9 cells infected

  Recombinant baculovirus infects moth cells in the S. frugiperda (Sf9) expression system.

  
• 3

  Spike gene enters Sf9 cell nucleus

  Spike DNA is transcribed.

  
• 4

  Sf9 cells produce spike proteins

  Spike proteins are expressed in their native trimer conformation.

  
• 5

  Nanoparticle formation

  Spike protein trimers are harvested. Vaccine nanoparticles assemble as spike protein trimers arranged around a Polysorbate 80 (PS80) core.

  
• 6

  Final vaccine

  Vaccine nanoparticles are mixed with Matrix-M^TM adjuvant to create ready-to-use NVX-CoV2373 vaccine.

  

COVID-19 continues to evolve around the world and is responsible for millions of deaths.¹ Our NVX-CoV2373 vaccine candidate has been shown to produce robust, functional immune responses in diverse clinical trial populations.

Vaccines produced using Novavax' technology are stable at standard refrigeration temperatures, enabling NVX-CoV2373 to reach people around the world.